Crescent Biopharma, Inc. (CBIO) stock
CBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 10/30
$14.37−0.39 (-2.61%)
Close on Nov 12, 2026Market cap $533.76MP/E –Yield –
Crescent Biopharma enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Crescent Biopharma's enterprise value was $237.95M on Nov 11, 2026, against $75.82M a year earlier. Over the last 5 years it ranged from -$35.77K to $19.28B, with a median of $2.62B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $237.95M | +655.4% |
| 2025 | Dec 31, 2025 | $31.50M | -98.0% |
| 2024 | Dec 31, 2024 | $1.61B | -89.4% |
| 2023 | Dec 29, 2023 | $15.14B | -4.4% |
| 2022 | Dec 30, 2022 | $15.83B | +115.5% |
| 2021 | Dec 31, 2021 | $7.35B | -58.8% |
| 2020 | Dec 31, 2020 | $17.84B | -21.6% |
| 2019 | Dec 31, 2019 | $22.77B | -44.0% |
| 2018 | Dec 31, 2018 | $40.63B | -25.9% |
| 2017 | Dec 29, 2017 | $54.85B | +291.2% |
| 2016 | Dec 30, 2016 | $14.02B | +29.4% |
| 2015 | Dec 31, 2015 | $10.84B | -20.0% |
| 2014 | Dec 31, 2014 | $13.54B | – |
See a number that looks wrong?